• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (6): 781-786.DOI: 10.3969/j.issn.1671-2587.2024.06.012

Previous Articles     Next Articles

Assessing the Residual Risk of Hepatitis B Virus Transmission via Blood Transfusion in 21 Chinese Blood Centers from 2018 to 2022

GUO Rui, HOU Yun, SU Changshan, et al   

  1. Handan Central Blood Station, Handan 056001
  • Received:2024-06-10 Online:2024-12-20 Published:2024-12-20

Abstract: Objective To analyze the residual risk (RR) of hepatitis B virus (HBV) transmission after blood transfusion in 21 selected blood centers across China. Methods We used the unqualified rate of hepatitis B surface antigen detected by enzyme-linked immunosorbent assay (ELISA) among repeat blood donors, the proportion of ELISA-negative but HBV DNA-positive samples, and the rate of first-time blood donors reported by the national information management system. Additionally, we applied the incidence/window period model to assess the temporal trends of HBV residual risk over the study period.Results Between 2018 and 2022, the RR of of HBV among blood donors in the 21 participating blood centers were (358.36~2 816.56)/(million person·year) (106py), (69.56~1 794.90)/106py, (50.75~1 153.05)/106py, (55.72~1 745.93)/106py, and (52.27~2 133.95)/106py. Overall, the 5-year trend in HBV residual risk across all the 21 centers did not demonstrate statistical significance ( χ2=0.663, P=0.416). However, the trend change in 14 of these centers was found to be statistically significant (P<0.05). Conclusion The RR of HBV differs greatly among the 21 evaluated blood centers. Given this variability, it is imperative for all regions to promptly adjust their blood screening strategies in accordance with their local laboratory capabilities, thus minimizing the RR of HBV transmission by blood transfusion and ensuring the blood safety.

Key words: Residual risk of blood transfusion, Hepatitis B virus, Blood screening strategy, Nucleic acid test

CLC Number: